Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel and Lapatinib in HER2+ MBC With Brain Metastases
NCT01934894Phase 2Terminated
- Sponsor
- SCRI Development Innovations
- Start
- May 2014
- Primary completion
- Feb 2016
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of cabazitaxel in breast cancer, brain metastases, sponsored by SCRI Development Innovations. Started May 2014; status: terminated.
02
Drugs
cabazitaxel
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on NCT01934894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01934894.